ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
NARFL Knockout Triggers Ferroptosis-Driven Vascular Endothelial Dysfunction.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NARFL Knockout Triggers Ferroptosis-Driven Vascular Endothelial Dysfunction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lactate and Lactylation in Pulmonary Hypertension: Comprehensive Landscape and Future Perspectives.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Nuclear prelamin A recognition factor-like (NARFL) is a core component of the cytosolic iron-sulfur (Fe-S) protein assembly (CIA) system. Yet, its role in vascular pathophysiology remains poorly defined. This study demonstrates that NARFL deficiency triggers ferroptosis, leading to severe vascular endothelial dysfunction across species. In zebrafish, narfl knockout causes embryonic lethality, accompanied by neurovascular defects, blood-brain barrier disruption, and aberrant hemodynamics. Similarly, knockout of the murine ortholog (Ciao3) results in mid-gestational embryonic lethality due to impaired vascular development and endothelial progenitor cell maturation. Mechanistically, NARFL deficiency disrupts CIA complex assembly, compromising Fe-S cluster transfer to client apo-proteins and leading to a functional shift of cytosolic aconitase (ACO) to iron regulatory protein 1 (IRP1), causing iron overload, heightened oxidative stress, and lipid peroxidation. Consequently, key anti-ferroptotic defenses are suppressed, culminating in endothelial ferroptosis. This pathway is conserved in human endothelial cells, where NARFL deficiency recapitulates the ferroptotic phenotype and functional impairments, which are rescued by the ferroptosis inhibitor. Clinically, specific NARFL polymorphisms have been identified as conferring susceptibility to vascular endothelial disorders (pulmonary hypertension, epilepsy, and neurodegenerative diseases). The work unveils a novel CIA-ferroptosis-vascular axis, positioning NARFL as a critical guardian of endothelial health and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.